Month: March 2025

  • Low-fat vegan diet tied to improved insulin sensitivity for adults with type 1 diabetes

    Low-fat vegan diet tied to improved insulin sensitivity for adults with type 1 diabetes

    Summarize this content to 100 words

    April 23, 2024
    3 min read




    Add topic to email alerts


    Receive an email when new articles are posted on

    Please provide your email address to receive an email when new articles are posted on .


    data-action=”subscribe”>
    Subscribe

    We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio

    Key takeaways:

    A low-fat vegan diet for 12 weeks reduced total daily insulin needs for adults with type 1 diabetes.
    A low-fat vegan diet was linked to greater drops in total and HDL cholesterol than a portion-controlled diet.

    Eating a low-fat vegan diet induced a greater improvement in insulin sensitivity and a larger reduction in total daily insulin dose than a portion-controlled diet for adults with type 1 diabetes, according to study findings.
    “With type 1 diabetes rates projected to possibly increase more than 100% in the next 15 years and the cost of insulin remaining stubbornly high, physicians should counsel patients with type 1 diabetes to try a low-fat vegan diet to not only help reduce their insulin requirements, but to reduce their heart disease risk and improve their overall health,” Hana Kahleova, MD, PhD, director of clinical research for the Physicians Committee for Responsible Medicine, told Healio.











    Kahleova and colleagues conducted a single-center randomized clinical trial that enrolled 58 adults aged 18 years and older with type 1 diabetes and a stable insulin regimen for at least 3 months. Participants were randomly assigned, 1:1, to eat a low-fat vegan diet consisting of vegetables, grains, legumes and fruits or a portion-controlled diet with individualized eating plans that reduced daily energy intake by 500 kcal to 1,000 kcal per day while keeping carbohydrate intake stable. All adults received weekly online nutrition education classes and support from registered dietitians. Total daily insulin dose, insulin sensitivity as measured by carbohydrate-to-insulin ratio, body weight and HbA1c were collected at baseline and 12 weeks. A staff member collected dietary intake data. Physical activity was self-reported. All participants wore a continuous glucose monitor during the study.
    The findings were published in Clinical Diabetes.
    There were 35 adults who completed the study, including 18 in the low-fat vegan diet group and 17 in the portion-controlled diet group. Adults eating a vegan diet had a greater reduction in body weight (mean difference, –4.3 kg; 95% CI, –6.1 to –2.4; P < .001) and BMI (mean difference, –1.6 kg/m2; 95% CI, –2.2 to –0.9; P < .001) than the portion-control group.
    A greater decline in total daily insulin dose was observed with a vegan diet compared with a portion-controlled diet (mean difference, –10.7 U; 95% CI, –21.3 to –0.2; P = .046). Adults in the vegan diet group had a greater increase in insulin sensitivity than the portion-control diet group (mean difference, 8.2 g of carbohydrate per unit of insulin; 95% CI, 3.6-12.8; P = .001). There were no differences for change in HbA1c or CGM metrics between the two groups.
    Changes in total daily insulin dose and insulin sensitivity correlated with changes in body weight. Each 1 kg of body weight loss was associated with a 2.16 U decrease in daily insulin dose and a 0.9 U increase in insulin sensitivity. Changes in insulin sensitivity correlated with changes in carbohydrate and fiber intake. Each 10 g increase in carbohydrate intake was associated with a 0.42 g increase in carbohydrate per unit of insulin. Each 10 g increase in fiber intake was associated with an increase of 4.29 g of carbohydrate per unit of insulin.
    “We knew from our previous research studies that a low-fat vegan diet improved insulin sensitivity, lowered weight and improved cardiovascular health in people with type 2 diabetes, so we were hopeful that we would see similar improvements in patients with type 1 diabetes,” Kahleova said. “We were pleased to see how dramatically a low-fat vegan diet improved insulin sensitivity and reduced insulin needs in people with type 1 diabetes.”
    Adults eating a vegan diet had greater declines in total cholesterol (mean difference, –21.4 mg/dL; 95% CI, –35.6 to –7.2; P = .004) and HDL cholesterol (mean difference, –9 mg/dL; 95% CI, –14.5 to –3.4; P = .003). No differences in LDL cholesterol or triglycerides were observed between the two groups.
    Kahleova said the findings need to be replicated in a larger study.

    Published by:


    Sources/DisclosuresCollapse


    Disclosures:
    Kahleova reports receiving compensation from the Physicians Committee for Responsible Medicine for working on the study. Please see the study for all other authors’ relevant financial disclosures.




    Add topic to email alerts


    Receive an email when new articles are posted on

    Please provide your email address to receive an email when new articles are posted on .


    data-action=”subscribe”>
    Subscribe

    We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio

    Source link

  • CIA’s mind-control projects offer lessons to a psychiatrist in training

    CIA’s mind-control projects offer lessons to a psychiatrist in training

    Summarize this content to 100 words
    My chief resident gave me a strange look when I arrived for another day of work at the Mayo Clinic one morning.
    “Something you’re not telling us?” she asked, gesturing to the two letters on my desk from the Central Intelligence Agency. The jokes — about how I was secretly working for America’s international spy service — wrote themselves. I laughed along.
    The letters were responses to Freedom of Information Act (FOIA) requests I had placed months earlier. Along with my clinical duties as a third-year psychiatry resident, I’d been conducting a one-person investigation into the relationship between the Mayo Clinic and the CIA’s Cold War-era mind control programs. Along the way, I became convinced that the study of psychiatry’s past can help psychiatrists-in-training learn to think critically about their work.
    During my final year of medical school, I became fascinated by the troubled history of my chosen profession, hoping to reckon with — and learn from — the mistakes of previous generations of psychiatrists. In the face of immense suffering, some had reached desperately for any treatments they thought could help their patients, despite limited evidence for their safety and efficacy. Some, like insulin coma and lobotomy, often caused irreparable harm. The impulse behind these therapies — to do something, anything — resonated with me during my intern year, treating patients with severe mental illness in the inpatient unit.

    Effective control of symptoms had to be balanced with the long list of adverse effects medications could cause. Providing good care, I learned, meant learning to live with imperfect outcomes, especially in the cases where the risks of pursuing a complete remission of symptoms outweighed the potential benefits of doing this.
    Harder to understand were past instances where psychiatrists had allowed their skills to be used as tools of oppression and social control. In Nazi Germany, psychiatrists participated in euthanasia and sterilization of individuals with mental illness. In the Soviet Union, political dissidents were confined to psychiatric hospitals. These abuses were not limited to other nations. During the 1950s and 1960s, psychiatrists at America’s top academic institutions supported the CIA’s ARTICHOKE and MK-ULTRA projects, which aimed to identify new methods of controlling thought and behavior. This work often involved experimentation on vulnerable people, such as those who were incarcerated or in psychiatric wards. The CIA justified these projects with claims that our Cold War adversaries were already well ahead of us in the “brainwashing” arms race, giving them the upper hand in a conflict with existential stakes.
    I became curious about whether my own institution had been involved in these disturbing programs. I learned that Mayo Clinic researchers, including many psychiatrists, had conducted extensive research on deep brain stimulation, hypnosis, and psychedelic drugs — all of which the CIA attempted to exploit for their mind control programs.
    I reached out to Dr. Colin Ross, a psychiatrist and historian whose book “The CIA doctors: Human Rights Violations by American Psychiatrists” chronicles the many connections between the worlds of academic psychiatry and clandestine intelligence during the Cold War. Ross had not found evidence of a relationship between the CIA and the Mayo Clinic, but he found the possibility plausible and encouraged me to keep digging.

    Excited by the prospect of uncovering something new about this dark chapter in the history of psychiatry, I spent increasing amounts of my free time squinting at faded CIA documents, making regular visits to Mayo’s archives, and learning how to file the FOIA requests that raised eyebrows in the resident workroom. My whiteboard filled up with a tangle of names, dates, and shadowy government agencies, even as I failed to turn up solid evidence of the connections I was searching for. My FOIA requests resulted in cryptic responses that the CIA could neither “confirm or deny” the existence of records on individuals I suspected were involved.
    Eventually, I found two versions of a long report by CIA personnel describing a visit to an institution referred to as “the Clinic” in April 1955 to discuss matters related to “ARTICHOKE and other programs of interest to us.” While heavily redacted, every unclassified detail lined up with the Mayo Clinic in the mid-1950s, suggesting — but not proving — that my suspicions had been correct.
    The document describes two faculty members named Bickford and Faulconer who had invented an “automatic anesthetic machine,” as well as a chief of psychiatry fascinated by the use of psychotropic mushrooms by Siberian tribes, and a former chief of anesthesiology who popularized the use of sodium pentothal in his field. Even the number of seats in the then-new Medical Sciences Building and the vast network of pneumatic tubes through which medical records were sent between hospitals described in the report are consistent with Mayo Clinic during this period. These are only a few of the details in the report I was able to link to the Mayo Clinic.
    The report documents meetings between CIA operatives and two physicians — including the “Chief of Psychiatry” and “former Chief of Anesthesiology” — who were both enthusiastic about supporting the CIA’s mission, though at times were ambivalent about the ethical implications of doing so.

    I found the matter-of-fact manner in which these physicians expounded on how medical science could be repurposed for coercion and domination jarring and nauseating to read. One faculty member reportedly believed that sensory deprivation, in combination with LSD, mescaline, and other psychotropic drugs, might be developed into a highly effective “intelligence weapon” of great promise for use on “unwilling or even violently objecting subjects.” The merits of various other psychiatric techniques, such as electroconvulsive therapy and frontal lobotomy, were discussed at length; the latter was written off not for humanitarian reasons, but because it was too unpredictable and technically complex.
    More unnerving than the details of these discussions, however, was the fact that the values and motivations of these physicians were far more relatable than I’d expected them to be. They were aware they were on difficult ethical terrain and were attempting to strike a delicate balance between their duty to their country — then engaged in a conflict many believed could lead to nuclear war — and their duty to do no harm. They were wary of conducting human experimentation to support the CIA’s brainwashing efforts, and “made it clear that their work was to help those that were ill and pointed out that their specialties were all aimed in that direction.”
    I found no evidence they did anything other than provide advice and offer material and intellectual support in the future. While other individuals and institutions who supported these projects received substantial grant funding, these doctors refused any compensation. They made it clear to their CIA visitors that they were motivated only by patriotism.
    Though that does not excuse their actions, the moral ambivalence of the physicians at “the Clinic” made it far easier to imagine me or my colleagues in their position. Psychiatrists in both clinical and research settings have to live with ambiguity, and are often forced to make difficult ethical decisions based on incomplete evidence. It made me wonder what treatments and research practices that are now widely accepted in psychiatry will be hard to justify to the next generation of mental health professionals.
    Studying the strange and often disturbing history of psychiatry has helped me reflect critically on my actions as a clinician and researcher, a view echoed by the Mayo Clinic’s current chair of psychiatry, Dr. Jeffrey Staab, with whom I shared my findings. “You’re quite right that we can and should learn from our past, especially from decisions that were made in difficult situations in which multiple ‘right things’ motivated our predecessors,” he wrote to me by email.

    UPCOMING EVENT
    Connect with today’s innovators & tomorrow’s thought leaders
    We’re hosting events nationwide (and virtually) to tackle the biggest questions in health and medicine. Browse our upcoming events to see what’s on the horizon.

    Mayo Clinic’s director of communications for media relations declined to comment on whether Mayo collaborated with the CIA on their mind control research during the 1950s. A CIA spokesperson also declined to comment on whether or not any such collaboration took place, but sent me the following statement that blandly recapitulates the facts but offers no insight: “The MKULTRA program ran from 1953 until the lack of productive results and ethical concerns about unwitting testing led to its cessation in 1963. It was reauthorized as MKSEARCH in 1965 on the understanding that no further experimentation on unwitting subjects was authorized. From 1965 until 1972, all subjects were witting, and CIA ceased all human experimentation in 1972. CIA is committed to transparency regarding this chapter of its history, including by declassifying information on the programs and making it publicly available on CIA.gov.”
    The CIA’s true commitment to transparency on these matters is open to debate: many of the documents describing these programs were destroyed in 1973 at the order of Richard Helms, who was then the CIA’s director. Among the surviving documents that have been declassified, many contain substantial redactions.
    There is evidence that incorporating reflection-based learning in medical residency programs can increase empathy and improve the ability of trainees to manage complex and challenging situations. Based on my experiences investigating a possible shadowy connection between the Mayo Clinic and the CIA, I believe that residency programs should consider creating opportunities for psychiatrists-in-training to study the troubled history of their profession, which may help them learn to approach their work with humility, humanity, and a healthy skepticism of the status quo.
    Casimir Klim is a fourth-year psychiatry resident at the Mayo Clinic.

    window.statGlobal = window.statGlobal || { };
    window.statGlobal.analytics = window.statGlobal.analytics || { };

    window.statGlobal.analytics.fbq = function( eventName, parameters ) {
    jQuery.ajax( {
    url: ‘/wp-json/stat-analytics/v1/facebook-pixel’,
    type: ‘POST’,
    data: {
    event_name: !eventName ? null : eventName,
    parameters: !parameters ? {} : parameters,
    source_url: window.location.href
    },
    success: function( data, textStatus, jqXHR ) {
    //console.log( data );
    },
    error: function ( jqXHR, textStatus, errorThrown ) {
    //console.log( jqXHR );
    }
    } );
    };

    jQuery( window ).on( ‘load’, function() {
    if ( !window.bgmpGdpr || window.bgmpGdpr.isOptedOut() ) {
    return;
    }

    !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function(){n.callMethod?
    n.callMethod.apply(n,arguments):n.queue.push(arguments)};if(!f._fbq)f._fbq=n;
    n.push=n;n.loaded=!0;n.version=’2.0′;n.queue=[];t=b.createElement(e);t.async=!0;
    t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
    document,’script’,’https://connect.facebook.net/en_US/fbevents.js’);

    fbq( ‘init’, ‘436331036555416’ );
    fbq( ‘track’, ‘PageView’ );

    document.addEventListener( ‘stat-hubspot-signup-subscribed’, () => {
    // Successful HubSpot newsletter signup AJAX form submission.
    window.statGlobal.analytics.fbq( ‘Lead’ );
    } );
    } );

    Source link

  • Europe is seeing “devastating” rise in health harms from extreme weather events, experts warn

    Europe is seeing “devastating” rise in health harms from extreme weather events, experts warn

    Summarize this content to 100 words The number of adverse impacts on health related to extreme weather and climate events is continuing to rise in Europe, an EU report1 has found.The report from the Copernicus Climate Change Service (C3S) said that vulnerable groups, the public, and some healthcare providers are underestimating the potential risks from extreme heat, a situation that experts said needs to change.The report estimates that there were between 55 000 and 72 000 deaths because of heat waves in the summer of 2022, the most recent year for which data are available. It highlighted that in the past 20 years, heat related deaths have increased in 94% of European regions. In the period between 2000 and 2020, heat related mortality increased by around 30% in the World …

    Source link

  • Biden admin issues rule protecting abortion privacy

    Biden admin issues rule protecting abortion privacy

    Summarize this content to 100 words

    Credit: Unsplash/CC0 Public Domain

    President Joe Biden’s administration announced a new rule Monday to protect the privacy of women who go out of their home state to have legal abortions, amid fears they could be prosecuted upon their return.

    The move comes as reproductive rights take center stage in the November presidential election, following a pivotal court decision that abolished or severely curtailed legal abortion in 21 states.
    “No one should have to live in fear that their conversations with their doctor or that their medical claims data might be used to target or track them,” Melanie Fontes Rainer of the Office for Civil Rights told reporters.
    The rule prohibits the disclosure of private health information sought to investigate individuals who seek or obtain reproductive health services that are lawful. It also applies to health care providers.
    Rainer urged women to come forward and file a complaint if they believed their privacy rights had been violated.
    The Health and Human Services agency received almost 30,000 public comments before finalizing its new rule, which strengthens the Health Insurance Portability Act (HIPAA) of 1996.
    In 2022, conservative judges appointed by former President Donald Trump helped strike down a half-century of legal precedent that upheld the constitutional right to abortion, sparking widespread outrage.
    Women in Republican-controlled states have since faced problems accessing reproductive care, including for non-viable pregnancies and even IVF treatment.
    Abortion rights have become a cornerstone of President Biden’s re-election campaign, and the issue helped Democrats outperform expectations in the 2022 midterm vote.

    © 2024 AFP

    Citation:
    Biden admin issues rule protecting abortion privacy (2024, April 23)
    retrieved 23 April 2024
    from https://medicalxpress.com/news/2024-04-biden-admin-issues-abortion-privacy.html

    This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
    part may be reproduced without the written permission. The content is provided for information purposes only.

    Source link

  • Sapio Sciences Launches New Multimodal Registration Capabilities

    Sapio Sciences Launches New Multimodal Registration Capabilities

    Summarize this content to 100 words

    Sapio Sciences has enhanced its lab informatics platform with new multimodal entity registration capabilities for diverse product types, including small and large molecules and conjugates.

    Image Credit: Sapio Sciences

    BALTIMORE, MD, April 23, 2024 — Sapio Sciences, the science-awareTM lab informatics platform, today announced the launch of its new multimodal registration capabilities. This new functionality unifies small-molecule, large-molecule, and multimodal discovery workflows, including entity registration, on a single platform. With these latest features, Sapio is helping R&D teams overcome the collaboration and efficiency challenges traditionally associated with the development of multimodal therapies and products.   

    New modalities, such as recombinant proteins, peptides and engineered antibodies are key drivers of biopharmaceutical industry growth. According to BCG, over the past few years, revenues from new-modality products increased by $60 billion, while revenues from conventional products declined by $10 billion. Furthermore, BCG projects that the percentage value of new modalities in the five-year forward pipeline between 2019 and 2023 will increase from 41% to 56%, far outpacing conventional ones.

    “The days of viewing drug discovery through the separate lenses of small molecules and large molecules are outdated,” said Kevin Cramer, president and CEO of Sapio Sciences. “Today, drug discovery in biopharma is increasingly multimodal, and leading-edge laboratories require a single unified informatics platform that supports small-molecule, large-molecule, and new modality discovery workflows, including registration.”

    Today, companies typically use separate registration systems, one for small molecules and another for large molecules. For multimodal discovery, separate registration becomes problematic. A unified registration system solves this by enabling researchers from diverse departments such as chemistry and molecular biology to work together on new modalities seamlessly, manage all data in one place, have one system for regulatory compliance, and collaborate with a single source of truth.

    The foundation of the Sapio Platform is a single materials management system that does not distinguish between small-molecule, large-molecule, or multimodal entities — rather, they are all collected and managed as molecular materials with attributes that record the unique characteristics of each type of entity. Uniquely, Sapio also connects its sample management with registered entities for seamless data visualizations and traceability.  As a result, chemists and biologists can work together on a single, unified drug discovery platform that combines Sapio LIMS™, Sapio ELN™ and Sapio Jarvis™ to integrate and harmonize collective scientific data across the laboratory informatics enterprise.

    New biotech ventures will want to adopt the Sapio Platform now to address leading-edge new modality drug discovery opportunities and position themselves for accelerated discovery and insights from day one. Established biopharma enterprises will want to reassess the limitations and risks of currently deployed separate chemistry- and biology-centric informatics and evaluate the benefits and advantages of a single unified lab informatics platform from Sapio to optimize leading-edge multimodal drug discovery.

    About Sapio Sciences

    Sapio Sciences’ mission is to improve lives by accelerating discovery, and because science is complex, Sapio makes technology simple. Sapio is a global business offering an all-in-one science-awareTM lab informatics platform combining cloud-based LIMS, ELN, and Jarvis data solutions.

    Sapio serves some of the largest global and specialist brands, including biopharma, CRO/CDMOs and clinical diagnostic labs across NGS genomic sequencing, bioanalysis, bioprocessing, chemistry, stability, histopathology, and in vivo studies.

    Customers love Sapio’s platform because it is robust, scalable, and with no-code configuration, can quickly adapt to meet unique needs. For more information, visit www.sapiosciences.com and follow us on LinkedIn.

    Source link

  • Less Gut Microbial Diversity in Patients With Prediabetes

    Less Gut Microbial Diversity in Patients With Prediabetes

    Summarize this content to 100 words TOPLINE:The gut microbiome biodiversity is lower in patients with prediabetes than in healthy individuals, and the microbiota have less of the species involved in key physiology and metabolism roles.METHODOLOGY:The association between gut bacteria, diet, glucose metabolism, and insulin resistance has been established, but there is a lack of research in the Asian population.Here, researchers sought to examine the differences in the gut microbiome composition between patients with prediabetes and healthy individuals.They evaluated 57 patients with prediabetes from the Taipei Tzu Chi Hospital and compared them to biobank data from 60 healthy adult individuals as the control population (all ages 18-65 years).All participants with prediabetes were required to keep a 3-day food record and collect fecal samples on the third day. Overall, 117 fecal samples were collected.In patients with prediabetes (fasting blood glucose levels of 100-126 mg/dL and A1c levels of 5.7%-6.5%), researchers compared gut microbiome differences by low and high intake in five nutrient groups — carbohydrate, protein, fat, fiber, and calories.TAKEAWAY:Bacterial biodiversity was lower in patients with prediabetes than in healthy individuals (Kruskal-Wallis test; P < .05).Biobank fecal sample data from healthy individuals vs patients with prediabetes showed higher relative abundances of bacteria that support the integrity of the intestinal mucosa such as Anaerostipes and Faecalibacterium. Healthy samples also showed higher relative abundance of Blautia, Bifidobacterium, Clostridium, Mediterraneibacter, and Butyricicoccus.Bacteroides, Phascolarctobacterium, Parabacteroides, and Paraprevotella were more abundant in the fecal samples obtained from patients with prediabetes.Fecal samples obtained from patients with prediabetes who followed a low- vs high-carbohydrate diet showed a higher gut microbiome diversity (Kruskal-Wallis test; P < .05) and relative abundance of Coprococcus, which works with dietary fiber to maintain gut barrier integrity.IN PRACTICE:”A balanced intake of appropriate nutrients and a high-fiber diet may be helpful in maintaining normal physiological metabolism and diversity in the intestinal bacteria,” the authors wrote.SOURCE:This study, led by Wei-Lin Chang, Department of Nutrition, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan, was published online in Nutrients.LIMITATIONS:The findings of this study may not be applicable to the general population as only a small sample of patients with prediabetes were recruited. The healthy control individuals in the biobank data set were younger (about 53 vs 58 years) and had higher body mass index (about 25 vs 23) than individuals in the prediabetes group. The dietary composition of either group was also not analyzed for differences, which may have led to differences in the gut microbiome composition observed in this study.DISCLOSURES:This work was supported by Taipei Tzu Chi Hospital. The authors declared no conflicts of interest.

    Source link

  • A Common Antibiotic Could Prevent, Treat Respiratory Illnesses Including COVID-19: Study

    A Common Antibiotic Could Prevent, Treat Respiratory Illnesses Including COVID-19: Study

    Summarize this content to 100 words
    A range of respiratory illnesses including COVID-19 and influenza could be prevented and treated using a widely available generic antibiotic, the results of a new study revealed.A team of researchers from Yale tested the effectiveness of antibiotic neomycin in animal models and found that administering the antibiotic neomycin through the nasal passage triggered a robust interferon-stimulated genes (ISG) line of defense against both SARS-CoV-2 and a highly virulent strain of influenza A virus. Also, administering neomycin intranasally significantly reduced the transmission of SARS-CoV-2 through contact in hamsters.The researchers also found a strong response when they applied over-the-counter Neosporin ointment to the noses of healthy humans. Neosporin contains three antibiotics neomycin, polymyxin B, and bacitracin which is typically used to prevent and treat bacterial skin infections.The results of the study were published in the journal Proceedings of the National Academy of Sciences.”This is an exciting finding, that a cheap over-the-counter antibiotic ointment can stimulate the human body to activate an antiviral response,” said Akiko Iwasaki, co-senior author of the study from the Yale School of Medicine, in a news release.”Our work supports both preventative and therapeutic actions of neomycin against viral diseases in animal models, and shows effective blocking of infection and transmission,” said Iwasaki.As of February 2024, there have been over 774.5 million documented cases of SARS-CoV-2 infections worldwide, resulting in 6.9 million deaths. Additionally, influenza viruses are responsible for approximately 5 million severe illness cases and 500,000 deaths annually on a global scale.The current treatment strategy focuses on stopping the progression of existing respiratory infections and involves the use of antivirals, monoclonal antibodies, and convalescent plasma therapy, which are delivered intravenously or orally.”A nasal-centered therapy has a much better chance of stopping infections before they can spread to the lower respiratory tract and cause severe diseases,” the news release stated.”This collaborative multi-disciplinary work combined important insights from animal pulmonary infection modeling experiments with human study evaluation of this intranasal approach to stimulate antiviral immunity,” former Yale researcher Charles Dela Cruz, who co-led the study, said.”Our findings suggest that we might be able to optimize this cheap and generic antibiotic to prevent viral diseases and their spread in human populations, especially in global communities with limited resources. This approach, because it is host-directed, should work no matter what the virus is,” Iwasaki said.

    Source link

  • Health Bulletin 23/ April/ 2024

    Health Bulletin 23/ April/ 2024

    Summarize this content to 100 words Health Bulletin 23/ April/ 2024 We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok

    Source link

  • MedCity FemFwd: What Needs To Happen to Improve Preeclampsia Rates?

    MedCity FemFwd: What Needs To Happen to Improve Preeclampsia Rates?

    Summarize this content to 100 words

    Welcome back to another episode of MedCity FemFwd, a podcast dedicated to discussing the breakthroughs and challenges in women’s health. In this episode, we’re joined by John Auerbach, senior vice president of federal health at consulting firm ICF. 

    Rates of preeclampsia — high blood pressure during pregnancy or after giving birth — are increasing in the U.S. In this episode, Auerbach discusses what needs to be done to improve preeclampsia rates.

    To hear the full episode and learn more, click here:

    Source link

  • National Healthcare Outcomes Conference looks at AI

    National Healthcare Outcomes Conference looks at AI

    Summarize this content to 100 words

    RCSI’s annual National Healthcare Outcomes Conference this year investigated the improvement of healthcare through AI

    Improving health outcomes through AI’ saw an expert line-up of speakers discussing issues ranging from AI and patient care, AI and population health, AI at the new Children’s Hospital, potentials and pitfalls of AI for healthcare, human-centred healthcare AI and patient experiences of AI.

    Source link

error: Content is protected !!